FY2024 EPS Estimates for Acelyrin Increased by HC Wainwright

Acelyrin, Inc. (NASDAQ:SLRN) – Stock analysts at HC Wainwright increased their FY2024 EPS estimates for Acelyrin in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.43) per share for the year, up from their prior estimate of ($3.35). HC Wainwright has a “Neutral” rating and a $8.00 price target on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.90) per share. HC Wainwright also issued estimates for Acelyrin’s Q4 2024 earnings at ($0.72) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.07) EPS and FY2028 earnings at ($1.30) EPS.

SLRN has been the topic of several other research reports. Wells Fargo & Company boosted their price target on shares of Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, October 16th. Piper Sandler lowered their price target on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Finally, Morgan Stanley lowered their price target on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Monday, August 19th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

Acelyrin Trading Down 0.9 %

Shares of SLRN stock opened at $4.65 on Monday. Acelyrin has a 1 year low of $3.36 and a 1 year high of $9.00. The firm’s fifty day simple moving average is $5.41 and its 200 day simple moving average is $5.03. The firm has a market capitalization of $466.52 million, a P/E ratio of -1.91 and a beta of 1.98.

Institutional Investors Weigh In On Acelyrin

Institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its position in Acelyrin by 118.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock worth $49,000 after buying an additional 3,921 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Acelyrin by 16.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,769 shares of the company’s stock worth $131,000 after buying an additional 4,163 shares in the last quarter. US Bancorp DE lifted its position in Acelyrin by 77.1% during the 3rd quarter. US Bancorp DE now owns 16,854 shares of the company’s stock worth $83,000 after buying an additional 7,336 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Acelyrin by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock worth $95,000 after buying an additional 7,560 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Acelyrin by 69.9% during the 1st quarter. ProShare Advisors LLC now owns 19,871 shares of the company’s stock worth $134,000 after buying an additional 8,176 shares in the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.